Does State Anxiety Affect the Outcome of an Oral Glucose Tolerance Test?

Durum Anksiyetesi Oral Glukoz Tolerans Test Sonuçlarını Etkiler mi?

Emre GEZER1, Yeliz DEMİRHAN1, Alev SELEK1, Zeynep CANTÜRK1, Berrin ÇETİNARSLAN1, Mehmet SÖZEN1, Ayfer PEKER KARATOPRAK2

1Kocaeli University, Faculty of Medicine, Department of Endocrinology and Metabolism, Kocaeli, Turkey
2Kocaeli University, Health Care Vocational School of Higher Education, Kocaeli, Turkey

ORCID ID: Emre Gezer 0000-0002-5340-6106, Yeliz Demirhan 0000-0003-3835-9820, Alev Selek 0000-0002-0646-8697, Zeynep Cantürk 0000-0001-7114-2565, Berrin Çetinarslan 0000-0002-8041-8161, Mehmet Sözen 0000-0002-8428-1115, Ayfer Peker Karatoprak 0000-0003-1723-2038

Cite this article as: Gezer E, et al. Does state anxiety affect the outcome of an oral glucose tolerance test? Med J West Black Sea. 2021;5(3):353-359.

Corresponding Author
Emre Gezer
E-mail
gezer_emre@hotmail.com

This study has been presented in 56th National Diabetes Congress. Online - 3-10 November 2020, Turkey.
INTRODUCTION

Anxiety can be described as a feeling of tension, worry or nervousness which is difficult to control causing unfavorable outcomes such as impairment or major distress. The outcomes of a recent survey reported in 2017 showed that an anxiety disorder was the most common mental health disorder, estimating the prevalence as 3.8% (284 million) of the global population (1). The association between anxiety and some other disorders, such as musculoskeletal disorders, hypertension, metabolic syndrome (MetS) and diabetes mellitus (DM) were demonstrated by a number of studies (2-4).

A recent study of 1255 patients showed a significant interaction between insulin resistance and social anxiety (5). Batelaan et al. had also demonstrated that anxiety is associated with increased risk for DM (6). Clinical chronic anxiety was also 20% higher among individuals with diabetes compared to those without diabetes in a surveillance study (7). Norepinephrinergic sympathetic nervous system and hypothalamic-pituitary-adrenal axis (HPA) are two different stress pathways which have been suspected to be involved in the development of MetS (8).

In addition to that, short-term norepinephrinergic sympathetic activity has been considered related to state anxiety which has been known to increase blood pressure, e.g., white coat hypertension (9). Some experimental studies reported that state anxiety is mediated by sympathetic effect of autonomic nervous system and that activity per se, triggers the elevation in blood pressure by secreting norepinephrine, regulated by the catechol-o-methyltransferase (COMT) gene (10). Based on these data in the literature, we conducted a prospective study investigating the effect of state anxiety of the subjects prior to oral glucose tolerance test (OGTT) on the test outcomes.

MATERIAL and METHODS

Individuals who referred to our Endocrinology clinic were evaluated between February-July 2020. The patients whom OGTT was indicated in the evaluation of impaired fasting glucose (IFG), obesity or reactive hypoglycemia were recruited for this prospective study. State-Trait Anxiety Inventory (STAI) TX-1 form was given to the patients who gave their informed consent to evaluate their state anxiety right before OGTT. STAI TX-1 form consisted 20 items and each one of them had weighted scores from 1 to 4. In order to obtain the scores for the S-anxiety, before starting the calculation, the scoring weights for the anxiety-absent items (1, 2, 5, 8, 10, 11, 15, 16, 19, 20) were reversed, i.e., 1, 2, 3, 4 were replaced by 4, 3, 2, 1, respectively. When this process was done, all scores were added which made up a cumulative state anxiety score (SAS) varying from a minimum of 20 to a maximum of 80.

Considering the patients’ self-declaration, a history of any psychiatric disease or a disease which causes insulin resistance, such as Cushing’s syndrome, acromegaly, polycystic ovary syndrome (PCOS); active glucocorticoid, anxiolytic, antidepressant or antipsychotic drug use, pregnancy, age less than 18 years were the exclusion criteria of our study. OGTTs were performed by the same nurse and in the same test room during this study. 5 groups were established according to OGTT outcomes: Normal - fasting plasma glucose (FPG) level < 100 mg/dL and 2-h plasma glucose (PG) level < 140 mg/dL, IFG - FPG level between 100 - 125 mg/dL and 2-h PG level < 140 mg/dL, impaired glucose tolerance (IGT) - FPG level < 100 mg/dL and 2-h PG level between 140 - 199 mg/dL, IFG and IGT - FPG level between 100 - 125 mg/dL and 2-h PG level between 140 - 199 mg/dL, and DM - FPG level ≥ 126 mg/dL or 2-h PG level ≥ 200 mg/dL. In addition to OGTT results and STAI scale scores, patients’ demographic characteristics including sex, education and marital status, history of diabetes in the first-degree relatives were noted. Height, weight and waist circumference of the patients were measured and body mass index (BMI) was calculated. There was no routine pre-test psychiatric evaluation to diagnose any unrevealed psychiatric disorder.

All statistical analyses were performed using the SPSS for Windows, version 21.0 (IBM Inc., Chicago, IL, USA). The Kolmogorov-Smirnov and the Shapiro-Wilk tests were used to assess the assumption of normality. Continuous variables were presented depending on normal distribution; normally distributed data as mean±standard deviation (SD)
Anxiety and Oral Glucose Tolerance Test

Ethical approval was obtained from the ethics committee of Kocaeli University, Faculty of Medicine (Date: 27.02.2020, No: KÜ GOKAEK 2020/3.09-2020/50) and all the patients gave their written informed consent to the study.

RESULTS

In this study, we included 516 patients to whom OGTT was performed and who completed STAI TX-1 form. Our group consisted of 158 (30.6%) men and 358 (69.4%) women with a mean ± SD age of 42.62 ± 14.20. Demographic and clinical characteristics including OGTT outcomes are described in Table 1. In unadjusted analyses, there was no significant correlation between SAS and age (r = 0.075, p = 0.089), education (r = -0.080, p = 0.071), BMI (r = -0.013, p = 0.765) and waist circumference (r = 0.004, p = 0.923).

As described in Table 2, median (25th-75th) SAS was 39 (32-45) in women and 38 (32-46) in men which showed no significant difference between two groups by Mann-Whitney U test (p = 0.926). Kruskal-Wallis test showed there

Table 1: Demographic characteristics, OGTT outcomes and STAI scores of the patients (n = 516).

| Characteristics                  | Values                        |
|----------------------------------|-------------------------------|
| Age (years ± SD)                 | 42.62 ± 14.20                 |
| Height (cm ± SD)                 | 166.44 ± 8.94                 |
| Weight (kg ± SD)                 | 84.44 ± 20.39                 |
| Waist circumference (cm ± SD)    | 104.85 ± 15.93                |
| Body Mass Index (kg/m² ± SD)     | 30.46 ± 6.96                  |
| STAI Score ± SD                  | 38.84 ± 9.41                  |

Demographics                  Cases [n (%)]                  

| Sex                          |                               |
|------------------------------|--------------------------------|
| Male                         | 158 (30.6)                     |
| Female                       | 358 (69.4)                     |
| Marital Status               |                                |
| Married                      | 373 (72.3)                     |
| Single                       | 110 (21.3)                     |
| Widow                        | 33 (6.4)                       |
| Education                    |                                |
| Nonliterate                  | 17 (3.3)                       |
| Literate                     | 12 (2.3)                       |
| Elementary school            | 112 (21.7)                     |
| Middle school                | 50 (9.7)                       |
| High school                  | 135 (26.2)                     |
| College                      | 190 (36.8)                     |
| Diabetes in first-degree relatives |                    |
| Yes                          | 271 (52.5)                     |
| No                           | 245 (47.5)                     |
| OGTT outcomes                |                                |
| Normal                       | 288 (56.1)                     |
| IFG                          | 30 (5.9)                       |
| IGT                          | 37 (7.2)                       |
| IFG and IGT                  | 9 (1.8)                        |
| DM                           | 149 (29.0)                     |

DM: Diabetes mellitus, IFG: Impaired fasting glucose, IPG: Impaired plasma glucose, OGTT: Oral glucose tolerance test, SD: Standard deviation. STAI: State-Trait Anxiety Inventory.

Table 2: The relationship between demographic characteristics of the patients and the STAI Score.

| STAI Score | p     |
|------------|-------|
| Sex        |       |
| Male       | 38.00 ± 9.22 | 0.926<sup>a</sup> |
| Female     | 39.00 ± 9.62 |
| Marital Status |       |
| Married    | 38.00 ± 9.22 | 0.993<sup>b</sup> |
| Single     | 39.00 ± 9.62 |
| Widow      | 40.00 ± 9.62 |
| Education  |       |
| Nonliterate| 41.00 ± 9.92 | 0.344<sup>b</sup> |
| Literate   | 43.00 ± 9.92 |
| Elementary school | 39.00 ± 9.92 |
| Middle school | 37.50 ± 9.92 |
| High school | 41.00 ± 9.92 |
| College    | 38.00 ± 9.92 |

Diabetes in first-degree relatives

| STAI Score | p     |
|------------|-------|
| Yes        | 38.51 ± 9.20 | 0.408<sup>c</sup> |
| No         | 39.20 ± 9.22 | 0.408<sup>c</sup> |

STAI: State-Trait Anxiety Inventory
<sup>a</sup>Data are expressed as median (25<sup>th</sup>-75<sup>th</sup> percentile)
<sup>b</sup>Data are expressed as mean ± standard deviation
<sup>c</sup>Evaluated by the Mann-Whitney U Test
<sup>d</sup>Evaluated by the Kruskal-Wallis Test
<sup>e</sup>Evaluated by the Independent Samples t Test
was no association between marital status of the patients and SAS \((p = 0.993)\) (Table 2). However, pairwise comparisons showed BMI and waist circumference in the group of married were significantly higher than those in the group of single \((p = 0.017\) and \(p < 0.001\), respectively). No significant relationship between SAS and education status/family history of DM was shown \((p = 0.344\) and \(p = 0.408\), respectively) (Table 2).

In multinomial logistic regression analysis as given in Table 3, there was no significant association between SAS and OGTT outcomes \((\text{IFG vs Normal OR 0.996, 95\% CI 0.956-1.037, } p = 0.883; \text{IGT vs Normal OR 1.014, 95\% CI 0.997-1.052, } p = 0.475; \text{IFG and IGT vs Normal OR 0.999, 95\% CI 0.931-1.071, } p = 0.972; \text{DM vs Normal OR 1.005, 95\% CI 0.982-1.027, } p = 0.689)\) after adjustment for all other covariates such as age, BMI, waist circumference and family history of DM. A significantly higher age and waist circumference in the DM group was demonstrated compared to the normal group \((\text{OR 1.043, 95\% CI 1.027-1.059, } p < 0.001\) and \(\text{OR 1.044, 95\% CI 1.019-1.069, } p = 0.001\), respectively).

While there was no correlation between OGTT outcomes and SAS \((p = 0.856)\) in unadjusted analysis, there was a significant relationship between OGTT outcomes and age, weight, BMI and waist circumference \((p < 0.001)\) (Table 4). Chi-square test demonstrated that the percentage of DM diagnosis following OGTT in the group of married was significantly higher than that in the group of single \((123/370 [33.2\%] \text{ and } 18/110 [12.1\%], \text{ respectively, } p = 0.003)\), as given in Table 4. There was no association between OGTT outcomes and family history of DM \((p = 0.220)\) (Table 4).

Additionally, the analyses showed that the odds of being diagnosed with DM in college graduates \((38/190 [20.0\%])\) was significantly lower compared to those in other education levels \((p = 0.007)\). According to the results calculated by Dunn’s test, all those significant correlations were in

### Table 3: Multinomial logistic regression analysis for the factors related with OGTT outcomes.

| OGGT outcomes* | OR   | 95% CI for OR | p    |
|---------------|------|---------------|------|
| **IFG**       |      |               |      |
| Intercept     | 0.012|               |      |
| Age           | 1.011| 0.983-1.040   | 0.441|
| BMI           | 1.036| 0.951-1.129   | 0.414|
| Waist circumference | 1.003| 0.963-1.044   | 0.898|
| STAI score    | 0.996| 0.956-1.037   | 0.833|
| FH of DM (yes vs no) | 1.646| 0.750-3.614   | 0.214|
| **IGT**       |      |               |      |
| Intercept     | <0.001|              |      |
| Age           | 1.040| 1.013-1.066   | 0.003|
| BMI           | 0.985| 0.903-1.075   | 0.739|
| Waist circumference | 1.024| 0.984-1.065   | 0.241|
| STAI score    | 1.014| 0.977-1.052   | 0.475|
| FH of DM (yes vs no) | 1.424| 0.700-2.898   | 0.329|
| **IFG and IGT** | 0.058|               |      |
| Age           | 1.005| 0.958-1.055   | 0.832|
| BMI           | 1.041| 0.896-1.208   | 0.602|
| Waist circumference | 1.009| 0.939-1.083   | 0.811|
| STAI score    | 0.999| 0.931-1.071   | 0.972|
| FH of DM (yes vs no) | 0.471| 0.114-1.954   | 0.300|
| **DM**        |      |               |      |
| Intercept     | <0.001|              |      |
| Age           | 1.043| 1.027-1.059   | <0.001|
| BMI           | 0.974| 0.923-1.027   | 0.329|
| Waist circumference | 1.044| 1.019-1.069   | 0.001|
| STAI score    | 1.005| 0.982-1.027   | 0.689|
| FH of DM (yes vs no) | 1.205| 0.787-1.844   | 0.391|

*The reference category is: NORMAL

**BMI**: Body mass index, **CI**: Confidence interval, **DM**: Diabetes mellitus, **FH**: Family history, **IFG**: Impaired fasting glucose, **IGT**: Impaired glucose tolerance, **OGTT**: Oral glucose tolerance test, **OR**: Odds ratio, **STAI**: State-Trait Anxiety Inventory
Anxiety and Oral Glucose Tolerance Test

The first possible mechanism causing that correlation is the activation of the HPA axis by chronic clinical anxiety which induces the release of counter-regulatory hormones such as adrenalin, noradrenalin, glucagon, growth hormone and cortisol (12). When this protective mechanism becomes chronically active, predisposing factors for DM such as insulin resistance, exacerbation of abdominal fat deposition and dyslipidemia are triggered (13). In addition to that, in turn these counter-regulatory hormones and the outcomes induced by them such as larger waist circumference cause higher levels of inflammatory markers such as interleukin-6 and C-reactive protein which are responsible for a variety of metabolic dysfunctions (14,15). It should be underlined that all these findings are due to the effects of chronic clinical anxiety; however, in our study, it was shown that the short-term state anxiety prior to OGTT had no impact on insulin sensitivity and blood glucose level.

From another point of view, it was also suggested that diabetes led to anxiety. Clinical anxiety symptoms may develop at the time of diagnosis with DM or during the period after the diagnosis. The patients may possibly feel distressed about the management of the disease, undesirable lifestyle changes and the long-term diabetes-related micro and mac

Table 4: The association of OGTT outcomes with the demographic/clinical characteristics of the patients and the STAI score.

| OGTT Outcomes* | Normal | IFG | IGT | IFG&IGT | DM | p*  |
|----------------|--------|-----|-----|---------|----|-----|
| STAI Score     |        |     |     |         |    |     |
|                | 39.00  | 36.00| 41.00| 38.00   | 39.00| 0.856|
|                | (31.00-45.75) | (27.75-46.75) | (33.00-45.00) | (36.00-43.00) | (32.00-46.50) |
| Age            | 38.00  | 40.50| 45.00| 38.00   | 48.00| < 0.001|
|                | (27.25-49.00) | (33.50-50.00) | (39.00-55.50) | (28.50-52.00) | (38.50-58.50) |
| Weight         | 77.00  | 85.50| 88.00| 81.00   | 88.00| < 0.001|
|                | (67.00-94.00) | (75.50-94.25) | (75.50-96.00) | (71.50-94.50) | (76.00-97.50) |
| BMI            | 28.12  | 29.92| 30.08| 32.39   | 31.24| < 0.001|
|                | (24.56-33.78) | (25.71-33.30) | (25.71-35.30) | (27.43-35.15) | (28.09-34.79) |
| Waist Circumference | 101.00 | 109.00| 104.00| 108.00 | 110.00| < 0.001|
|                | (92.00-111.75) | (97.75-113.25) | (98.50-113.00) | (95.50-116.00) | (100.00-118.50) |

| OGGT Outcomes* | Normal | IFG | IGT | IFG&IGT | DM | p** |
|----------------|--------|-----|-----|---------|----|-----|
| Marital Status |        |     |     |         |    |     |
| Married        | 191 (51.6) | 22 (5.9) | 30 (8.1) | 4 (1.1) | 123 (33.2) | 0.003 |
| Single         | 80 (72.7)  | 6 (5.5)  | 3 (2.7)  | 3 (2.7)  | 18 (16.4)  |     |
| Widow          | 17 (51.5)  | 2 (6.1)  | 4 (12.1) | 2 (6.1)  | 8 (24.2)   |     |
| Diabetes in first-degree relatives |        |     |     |         |    |     |
| Yes            | 141 (52.4) | 19 (7.1) | 22 (8.2) | 3 (1.1)  | 84 (32.2)  | 0.220 |
| No             | 147 (60.2) | 11 (4.5) | 15 (6.1) | 6 (2.5)  | 65 (26.6)  |     |

BMI: Body mass index, DM: Diabetes mellitus, IFG: Impaired fasting glucose, IGT: Impaired glucose tolerance, OGTT: Oral glucose tolerance test, STAI: State-Trait Anxiety Inventory

*Data are expressed as median (25th - 75th percentile), *Data are expressed as n (%) 
*Evaluated by the Kruskal-Wallis Test, **Evaluated by the Chi-Square Test
ro-vascular complications which causes poorer adherence to diabetes care regimens (16). Diabetes related anxiety was reported in approximately 60% of patients with DM and it was shown that anxiety provokes poorer glycemic control and higher incidence of diabetes-related complications (17).

Other considerable results in this study were the significant association between new-onset DM diagnosis according to OGTT outcomes and marital status/waist circumference. In adjusted analyses, only age and waist circumference were significantly higher in the diabetes group than those in the normal group, which may indicate waist circumference is one the most substantial predictive parameters for type 2 DM, even better predictor than BMI. In accordance with our finding, in a population-based cross-sectional study which was conducted in Iran, the authors reported waist circumference and waist-to-height ratio were slightly better discrimination parameters than BMI for diabetes (18).

In a brief review by Jawad and Kalra (19), the interaction between marriage and diabetes was discussed. Patients with diabetes may encounter some concerns and challenges which are derived from the fear of self-disclosure, subfertility, financial implication and lack of “marriageability”/ability to maintain a high level of marital quality. As a result, clinical anxiety could be elevated by all these factors disrupting the adherence to diabetes care regimens. Likewise, Liu et al. (20) emphasize the importance of marital quality for both the development and management of DM with a comprehensive analysis in a national longitudinal study. In agreement with those studies, the present study showed that the percentage of DM diagnosis following OGTT in the group of married was significantly higher than that in the group of single; however, there was no significant association between SAS and marital status. From these two findings, it can be concluded that aforementioned predisposing factors due to marriage might increase the odds for development of diabetes, despite even the absence of clinical anxiety. Moreover, alteration in eating habits and decline in frequency of daily exercise after getting married could be other factors increasing the development ratio of diabetes.

Our study demonstrated that test-dependent state anxiety had no impact on OGTT outcomes, unlike the effect of chronic clinical anxiety as described in the literature. Our primary aim was to enlighten that relationship between those two entities and in case of a presence of a significant association, conducting STAI-TX1 scale to subjects could be a routine procedure prior to OGTT and it could be postponed for the individuals with increased state anxiety score. According to our results, it can be concluded that evaluating the state anxiety of patients right before OGTT may not be required; however, it is worthwhile to remember the chronic anxiety could affect the outcomes of OGTT and a randomized prospective study is necessary to help determine if evaluating trait anxiety is required prior to OGTT.

**Acknowledgment**

We would like to thank our clinical secretaries, Mrs. Songül Gür and Mrs. Canan Ateşarslan for their assistance in organizing the subjects to complete the anxiety scale right before OGTT. Funding is not applicable for this study and the authors declare that they have no conflict of interest.

**Author Contributions**

Concept: Emre Gezer, Yeliz Demirhan, Design: Emre Gezer, Yeliz Demirhan, Supervision: Berrin Çetinarslan, Zeynep Cantürk, Alev Selek, Resources: Emre Gezer, Yeliz Demirhan, Ayfer Peker Karatoprak, Materials: Yeşim Yeliz Demirhan, Ayfer Peker Karatoprak, Data Collection and/or Processing: Yeliz Demirhan, Ayfer Peker Karatoprak, Analysis and/or Interpretation: Emre Gezer, Berrin Çetinarslan, Alev Selek, Zeynep Cantürk, Literature Search: Emre Gezer, Mehmet Sözen, Yeliz Demirhan, Writing Manuscript: Emre Gezer, Mehmet Sözen, Critical Review: Alev Selek, Berrin Çetinarslan, Zeynep Cantürk.

**Conflicts of Interest**

The authors declare that they have no conflict of interest.

**Financial Support**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Ethical Approval**

Approval was obtained from the ethics committee of Kocaeli University, Faculty of Medicine (Date:27.02.2020, No: KÜ GOKAEK 2020/3.09-2020/50)

**Review Process**

Extremely peer-reviewed and accepted.

**REFERENCES**

1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392(10159):1789-1858.

2. Scott KM, Lim C, Al-Hamzawi A, Alonso J, Bruffaerts R, Calsde-Almeida JM, Florescu S, de Girolamo G, Hu C, de Jonge P, Kawakami N, Medina-Mora ME, Moskalewicz J, Navarro-Mateu F, O’Neill S, Piazza M, Posada-Villa J, Torres Y, Kessler RC. Association of Mental Disorders With Subsequent Chronic Physical Conditions: World Mental Health Surveys From 17 Countries. JAMA Psychiatry 2016;73(2):150-158.

3. Tang F, Wang G, Lian Y. Association between anxiety and metabolic syndrome: A systematic review and meta-analysis of epidemiological studies. Psychoneuroendocrinology 2017;77:112-121.
4. Lemche AV, Chaban OS, Lemche E. Trait anxiety but not state anxiety level associates with biomarkers for hypertension in the metabolic syndrome. Psychophysiology 2016;53(6):914-920.

5. Jaremka LM, Pacanowski CR. Social anxiety symptoms moderate the link between obesity and metabolic function. Psychoneuroendocrinology 2019;110:104425.

6. Batelaan NM, Seldenrijk A, Bot M, van Balkom AJ, Penninx BW. Anxiety and new onset of cardiovascular disease: Critical review and meta-analysis. Br J Psychiatry 2016;208(3):223-231.

7. Li C, Barker L, Ford ES, Zhang X, Strine TW, Mokdad AH. Diabetes and anxiety in US adults: Findings from the 2006 behavioral risk factor surveillance system. Diabet Med 2008;25(7):878-881.

8. Lambert E, Dawood T, Straznicky N, Sari C, Schlaich M, Esler M, Lambert G. Association between the sympathetic firing pattern and anxiety level in patients with the metabolic syndrome and elevated blood pressure. J Hypertens 2010;28(3):543-550.

9. Ziegler MG, Elayan H, Milic M, Sun P, Gharraibeh M. Epinephrine and the metabolic syndrome. Curr Hypertens Rep 2012;14(1):1-7.

10. Fossum E, Høiegen A, Reims HM, Moan A, Rostrup M, Eide I, Kjeldsen SE. High screening blood pressure is related to sympathetic nervous system activity and insulin resistance in healthy young men. Blood Press 2004;13(2):89-94.

11. Głowinska A, Zielona-Jenek M, Pawelczyk A, Banaszewska BE. Determinants of emotional problems and mood disorders in women with polycystic ovary syndrome. Ginekol Pol 2016;87(6):405-410.

12. Powers SI, Laurent HK, Gunlicks-Stoessel M, Balaban S, Bent E. Depression and anxiety predict sex-specific cortisol responses to interpersonal stress. Psychoneuroendocrinology 2016;69:172-179.

13. Prpić-Križevac I, Caneci-Varžić S, Bilić-Ćurèić I. Hyperactivity of the hypothalamic-pituitary- adrenal axis in patients with type 2 diabetes and relations with insulin resistance and chronic complications. Wien Klin Wochenschr 2012;124(11-12):403-411.

14. Liukkonen T, Räsänen P, Jokelainen J, Leinonen M, Järvelin MR, Meyer-Rochow VB, Timonen M. The association between anxiety and C-reactive protein (CRP) levels: Results from the Northern Finland 1966 birth cohort study. Eur Psychiatry 2011;26(6):363-369.

15. Brunner EJ, Hemingway H, Walker BR, Page M, Clarke P, Juneja M, Shipley MJ, Kumari M, Andrew R, Seckl JR, Papadopoulos A, Checkley S, Rumley A, Lowe GD, Stansfeld SA, Marmot MG. Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: Nested case-control study. Circulation 2002;106(21):2659-2665.

16. Pouwer F. Should we screen for emotional distress in type 2 diabetes mellitus? Nat Rev Endocrinol 2009;5(12):665-71.

17. Bickett A, Tapp H. Anxiety and diabetes: Innovative approaches to management in primary care. Exp Biol Med 2016;241(15):1724-1731.

18. Hajian-Tilaki K, Heidari B. Is waist circumference a better predictor of diabetes than body mass index or waist-to-height ratio in Iranian adults? Int J Prev Med 2015;6:5.

19. Jawad F, Kaira S. Marriage and diabetes. Prim Care Diabetes 2019;9(6):6-8.

20. Liu H, Waite L, Shen S. Diabetes Risk and Disease Management in Later Life: A National Longitudinal Study of the Role of Marital Quality. J Gerontol B Psychol Sci Soc Sci 2016;71(6):1070-1080.